The court upheld the appeal of VšZP in the case of payment of medicine to a child patient with SMA – Domestic – News

The Regional Court in Bratislava upheld the appeal of the state General Health Insurance Company (VšZP) in the case of reimbursement of the drug Zolgensma to a child patient with spinal muscular atrophy (SMA) II. type. This was confirmed by Ivana Štefúnová from the VšZP communication department for TASR, the portal drew attention to it.

In March, the District Court of Bratislava V ordered the payment of the two-million-dollar medicine for the exception of the health insurance company in an urgent measure.

“The regional court changed the decision of the court of first instance and rejected the plaintiff’s proposal to order an urgent measure, thus confirming that the conditions for ordering it, and thus for the payment of the medicine, were not met. VšZP is reviewing the next steps,” she said.

archive of Monika Rischerová Read more The insurance company has to reimburse Editka for the drug worth two million. However, money may be lacking for others

VšZP does not register any other urgent measures for payment of uncategorized medicine. He believes that the court’s decision will contribute to the fact that medicines for exemption are approved exclusively according to the conditions that health insurance companies must comply with, and not under media and public pressure.

She declared that it is in her interest that all patients who can be helped have access to innovative medicines. “However, the options of health insurance companies are significantly limited by the budget and the set limits for uncategorized medicines, which the Ministry of Health should change without delay, through categorization or by creating a separate fund from which health insurance companies will be able to draw on exceptions until they enter the categorization,” she added. Štefúnová.

This year, the state health insurance company reimbursed Zolgensma to two more insured persons. She pointed out that they were diagnosed with type 1 SMA immediately after birth thanks to a pilot newborn screening. “VšZP granted the request for this drug, as based on medical evidence, the best treatment results can be achieved in patients with type 1 SMA when the drug is given to them before the 42nd day after birth,” pointed out Štefúnová.

VšZP declared that it supports the initiative of the Ministry of Health to make screening for the diagnosis of SMA a regular part of newborn screening covered by public health insurance. “At the same time, he is of the opinion that if treatment with a certain drug becomes the standard and only therapeutic alternative, the drug should be categorized and available to every patient who meets the indication criteria,” she added.

Source: Pravda – Správy by

*The article has been translated based on the content of Pravda – Správy by If there is any problem regarding the content, copyright, please leave a report below the article. We will try to process as quickly as possible to protect the rights of the author. Thank you very much!

*We just want readers to access information more quickly and easily with other multilingual content, instead of information only available in a certain language.

*We always respect the copyright of the content of the author and always include the original link of the source article.If the author disagrees, just leave the report below the article, the article will be edited or deleted at the request of the author. Thanks very much! Best regards!